Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report
Open Access
- 18 December 2006
- journal article
- case report
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 289
- https://doi.org/10.1186/1471-2407-6-289
Abstract
To date, there is no standard treatment for unresectable malignant peritoneal mesothelioma; either best supportive care or systemic chemotherapy with palliative intent are accepted options. Here, we report the case of a 79-year old patient with malignant peritoneal mesothelioma who was treated with pemetrexed single-agent and obtained an impressive long-lasting response. Single-agent pemetrexed is a treatment option for malignant peritoneal mesothelioma in selected elderly patients or in patients with unpaired performance status.Keywords
This publication has 8 references indexed in Scilit:
- Malignant mesotheliomaThe Lancet, 2005
- Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access ProgramClinical Lung Cancer, 2005
- Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal ChemotherapyJournal of Clinical Oncology, 2003
- The Immunohistochemical Diagnosis of MesotheliomaThe American Journal of Surgical Pathology, 2003
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- A review of peritoneal mesothelioma at the Washington Cancer InstituteSurgical Oncology Clinics of North America, 2003
- Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- The epidemiology of mesotheliomaSeminars in Oncology, 2002